(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
23 February 2012 (23.02.2012)

PCT

(10) International Publication Number
WO 2012/023113 A2

(51) **International Patent Classification**:
A61K 38/18 (2006.01)

(21) **International Application Number**:
PCT/IB2011/053638

(22) **International Filing Date**:
17 August 2011 (17.08.2011)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/375,636 20 August 2010 (20.08.2010) US

(71) **Applicant** *(for all designated States except US)*: **WYETH LLC** [US/US]; Five Giralda Farms, Madison, NJ 07940 (US).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **BERASI, Stephen Peter** [US/US]; Pfizer Global Research & Development, 87 Cambridge Park Drive, Cambridge, Massachusetts 02140 (US). **BROWN, Christopher Todd** [US/US]; Pfizer Global Research & Development, 87 Cambridge Park Drive, Cambridge, Massachusetts 02140 (US). **CAIN, Michael John** [US/US]; Pfizer Global Research & Development, 87 Cambridge Park Drive, Cambridge, Massachusetts 02140 (US). **CALABRO, Valerie Perrine** [FR/FR]; Avenue de Carro Residence "Le, Baoutailla", Apt. 34, F-13500 Carro (FR). **JUO, Zong Sean** [US/US]; Pfizer Global Research & Development, 87 Cambridge Park Drive, Cambridge, Massachusetts 02140 (US). **MARTINEZ, Robert Vincent Paul** [TT/US]; Pfizer Global Research & Development, 87 Cambridge Park Drive, Cambridge, MA 02140 (US). **SEEHERMAN, Howard Joel** [US/US]; Pfizer Global Research & Development, 87 Cambridge Park Drive, Cambridge, Massachusetts 02140 (US). **WOZNEY, John Martin** [US/US]; Pfizer Global Research & Development, 87 Cambridge Park Drive, Cambridge, Massachusetts 02140 (US).

(74) **Agent**: **BENSON, Gregg C.**; Pfizer Inc., Eastern Point Road, MS 9114, Groton, CT 06340 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the identity of the inventor (Rule 4.17(i))*

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) **Title**: DESIGNER OSTEOGENIC PROTEINS

(57) **Abstract**: The invention relates to novel designer osteogenic proteins having altered affinity for a cognate receptor, nucleic acids encoding the same, and methods of use therefor. More preferably, the novel designer osteogenic proteins are designer BMPs and have altered affinity for a cognate BMP receptor. The designer BMPs demonstrate altered biological characteristics and provide potential useful novel therapeutics.

WO 2012/023113 A2